AllerGen successfully completes mid-term review

Guest Contributor
December 1, 2015

AllerGen, the Allergy, Genes and Environment Network, has successfully passed its second mid-term review and will receive funding until 2019. Launched in 2005, the classic Network of Centres of Excellence (NCE) will receive the maximum funding allowable under (now modified) NCE rules. In 2012, it was awarded $36.6 million ($5.2 million annually) for its second seven-year tranche, which will take the McMaster Univ-based organization to FY18-19 (R$, March 29/12). Its last four years will see AllerGen scientists complete their research and focus on translating and commercializing key findings. Among its achievements to date are the Canadian Healthy Infant Longitudinal Development Study examining the early-life origins of allergies and asthma, and the Clinical Investigator Collaborative for Phase II trials of new drugs to better manage asthma and allergies....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.